## Phase I

- **Antibody-drug conjugate** (RG7882)[a] GYNECOLOGIC
- **Antibody-drug conjugate** (RG7986)[a] HEMATOLOGY
- **Anti-CD20/CD3 TCB** (RG6026) HEMATOLOGY
- **Anti-CD20/CD3 TDB** (RG7828) HEMATOLOGY
- **Anti-CD20** (RG7159) HEMATOLOGY
- **Anti-CD40 MAb** (RG7876) SOLID TUMOR
- **Anti-CEA CD3 TCB** (RG7802) SOLID TUMOR
- **Anti–FAP-IL2v FP** (RG7461) GENITOURINARY
- **Anti-TIGIT** (RG6058) SOLID TUMOR
- **Atezolizumab (anti-PDL1 MAb)** (RG7446) BREAST, GASTROINTESTINAL, GENITOURINARY (mCRPC), GYNECOLOGIC, HEMATOLOGY, LUNG, SOLID TUMOR
- **BET inhibitor** (RG6146)[b] HEMATOLOGY, SOLID TUMOR
- **Cergutuzumab amunaleukin (anti–CEA-IL2v)** (RG7813) SOLID TUMOR
- **ChK1 inhibitor** (RG7741)[c] SOLID TUMOR
- **Cobimetinib (MEK inhibitor)▼** (RG7421)[d] MELANOMA
- **Emactuzumab (anti–CSF-1R MAb)** (RG7155) SOLID TUMOR
- **FAP-DR5 biMAb** (RG7386) SOLID TUMOR
- **Glypican-3/CD3 biMAb** (CHU) SOLID TUMOR
- **Pan-RAF inhibitor** (RG6185)[e] SOLID TUMOR
- **Personalized cancer vaccine** (RG6180)[f] SOLID TUMOR
- **PI3K inhibitor** (RG6114) BREAST, SOLID TUMOR
- **RAF/MEK dual inhibitor** (CHU) SOLID TUMOR
- **Selective estrogen receptor degrader (SERD)** (RG6047)[g] BREAST
- **Venetoclax (BCL-2 inhibitor)▼** (RG7601)[h] HEMATOLOGY (AML, MDS)

## Phase II

- **Trastuzumab emtansine▼** (RG3502) BREAST
- **Atezolizumab (anti-PDL1 MAb)** (RG7446) BREAST, GASTROINTESTINAL, SOLID TUMOR
- **Cobimetinib (MEK inhibitor)▼** (RG7421)[d] BREAST
- **Codrituzumab (anti–glypican-3 MAb)** (RG7686) GASTROINTESTINAL
- **Ipatasertib (AKT inhibitor)** (RG7440)[c] BREAST
- **Polatuzumab vedotin (anti-CD79b ADC)** (RG7596)[a] HEMATOLOGY
- **Taselisib (PI3K inhibitor)** (RG7604) BREAST
- **Vanucizumab (anti–ANG2-VEGF biMAb)** (RG7221) GASTROINTESTINAL
- **Venetoclax (BCL-2 inhibitor)▼** (RG7601)[h] HEMATOLOGY (DLBCL, MDS)

## Phase III

- **Trastuzumab emtansine▼** (RG3502) BREAST
- **Atezolizumab (anti-PDL1 MAb)** (RG7446) BREAST, GASTROINTESTINAL, GENITOURINARY (mCRPC, RCC), GYNECOLOGIC, LUNG
- **Cobimetinib (MEK inhibitor)▼** (RG7421)[d] MELANOMA
- **Emicizumab** (RG6013) HEMATOLOGY
- **Idasanutlin (MDM2 antagonist)** (RG7388) HEMATOLOGY
- **Ipatasertib (AKT inhibitor)** (RG7440)[c] GENITOURINARY
- **Pertuzumab (anti-HER2 MAb)▼** (RG1273) BREAST, GASTROINTESTINAL
- **Taselisib (PI3K inhibitor)** (RG7604) BREAST
- **Vemurafenib** (RG7204) MELANOMA
- **Venetoclax (BCL-2 inhibitor)▼** (RG7601)[h] HEMATOLOGY (MM, AML, CLL)




**These compounds and their uses are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use.**

**The Oncology Pipeline information is consistent with the Roche first quarter results 2017 presentation (as of April 27, 2017).**

[a]Developed in collaboration with Seattle Genetics.
[b]Tensha acquisition.
[c]Developed in collaboration with Array BioPharma.
[d]Developed in collaboration with Exelixis.
[e]Hanmi.
[f]BioNtech.
[g]Seragon acquisition.
[h]Joint project with AbbVie, in collaboration with WEHI (The Walter and Eliza Hall Institute).
[i]Developed in collaboration with Chugai.

AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; DLBCL=diffuse large B-cell lymphoma; mCRPC=metastatic castration-resistant prostate cancer; MDS=myelodysplastic syndromes; MM=multiple myeloma; RCC=renal cell carcinoma.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

© 2017 F. Hoffmann-La Roche Ltd. All rights reserved. PR/aPDL1/1708/0007